Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

³úÁ¾¾ç¿¡¼­ µ¹¿¬º¯ÀÌÇü p53´Ü¹é ¹× PCNAÀÇ ¹ßÇöÇö»ó Expression of p53 Protein and PCNA in Brain Tumors

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1995³â 24±Ç 2È£ p.189 ~ 194
¼Ò¼Ó »ó¼¼Á¤º¸
±èÈ«¼ö ¾È¿µÈ¯/¹Ú¾ð¼·/¸ñÁøÈ£/¹Ú°ü/±è¿µ¹é/¹Îº´±¹/Ȳ¼º³²/¼®Á¾½Ä

Abstract


Formalin-fixed. paraffin-embedded samples of 32 brain tumors (8 meningiomas, 10 astrocytomas (low grade 5. anaplastic 5). 8 glioblastoma multiforme. 6 oligodendrogliomas (low grade 2. anaplastic 3) were investigated by immunocytochemistry with
monoclonal antibodies against p53 protein and proliferating cell nuclear antigen (PCNA).
Expression of p53 protein was detected in 1 of 5 cases (20%) of low grade astrocytomas. 2 of 5 cases (40%) of anaplastic astrocytoma. 4 of 8 cases (50%) of glioblastoma multiforme and 4 of 4 cases (100%) of malignant oligodendroglioma. All low
grade
oligodendrogliomas. meningiomas fail to express p53.
Expression of PCMA was detected in 3 of 8 cases of meningioma with very low labelling index (0-0.3). 2 of 5 cases of grade astrocytoma with low labelling index (1-11.3). 3 of 5 cases of anaplastic astrocytoma with middle labelling index (0-28.2).
6
of 8
cases of glioblastoma multiforme and 4 of 4 cases of malignant oligodendroglioma with high labelling index (0-92.3. 7.6-48.1). Expression of PCNA was not detected in low grade oligodendrogliomas.
Tumor group with high expression of p53 protein showed increment of PCNA expression. A strong positive correlation between tumor grade and extent of p53 protein and PCNA expression was found (p<0.002).

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS